| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1862 | 2020 |
| Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium P Grivas, AR Khaki, TM Wise-Draper, B French, C Hennessy, CY Hsu, ... Annals of oncology 32 (6), 787-800, 2021 | 297 | 2021 |
| A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma PJ Hosein, J Macintyre, C Kawamura, JC Maldonado, V Ernani, ... BMC cancer 12, 1-7, 2012 | 262 | 2012 |
| Effect of gemcitabine and nab-paclitaxel with or without hydroxychloroquine on patients with advanced pancreatic cancer: a phase 2 randomized clinical trial TB Karasic, MH O’Hara, A Loaiza-Bonilla, KA Reiss, UR Teitelbaum, ... JAMA oncology 5 (7), 993-998, 2019 | 241 | 2019 |
| Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ... JAMA oncology 7 (8), 1167-1175, 2021 | 176 | 2021 |
| A phase 2 study of vorinostat in acute myeloid leukemia EW Schaefer, A Loaiza-Bonilla, M Juckett, JF DiPersio, V Roy, J Slack, ... haematologica 94 (10), 1375, 2009 | 136 | 2009 |
| Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma N Dempsey, JC Maldonado, A Loaiza-Bonilla, M Velez, L Carcas, ... Pancreatology 15 (6), 667-673, 2015 | 89 | 2015 |
| Neoadjuvant therapy for gastric cancer: current evidence and future directions AD Newton, J Datta, A Loaiza-Bonilla, GC Karakousis, RE Roses Journal of gastrointestinal oncology 6 (5), 534, 2015 | 89 | 2015 |
| Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial JM Llovet, M Kudo, P Merle, T Meyer, S Qin, M Ikeda, R Xu, J Edeline, ... The Lancet Oncology 24 (12), 1399-1410, 2023 | 74 | 2023 |
| Percutaneous irreversible electroporation for the treatment of colorectal cancer liver metastases with a proposal for a new response evaluation system PJ Hosein, A Echenique, A Loaiza-Bonilla, T Froud, K Barbery, CMR Lima, ... Journal of vascular and interventional radiology 25 (8), 1233-1239. e2, 2014 | 60 | 2014 |
| Dramatic response to dabrafenib and trametinib combination in a BRAF V600E-mutated cholangiocarcinoma: implementation of a molecular tumour board and next-generation sequencing … A Loaiza-Bonilla, E Clayton, E Furth, M O’Hara, J Morrissette Ecancermedicalscience 8, 2014 | 59 | 2014 |
| A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma AL Windon, A Loaiza-Bonilla, CE Jensen, M Randall, JJD Morrissette, ... Journal of gastrointestinal oncology 9 (1), 1, 2018 | 57 | 2018 |
| SDHB mutation carriers with malignant pheochromocytoma respond better to CVD L Fishbein, S Ben-Maimon, S Keefe, K Cengel, DA Pryma, ... Endocrine-related cancer 24 (8), L51-L55, 2017 | 54 | 2017 |
| Racial disparities in COVID-19 outcomes among black and white patients with cancer J Fu, SA Reid, B French, C Hennessy, C Hwang, NT Gatson, N Duma, ... JAMA network open 5 (3), e224304-e224304, 2022 | 48 | 2022 |
| Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19 AL Schmidt, MD Tucker, Z Bakouny, C Labaki, CY Hsu, Y Shyr, ... JAMA network open 4 (11), e2134330-e2134330, 2021 | 41 | 2021 |
| KDR mutation as a novel predictive biomarker of exceptional response to regorafenib in metastatic colorectal cancer A Loaiza-Bonilla, CE Jensen, S Shroff, E Furth, PA Bonilla-Reyes, ... Cureus 8 (2), 2016 | 27 | 2016 |
| Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer S Palacio, A Loaiza-Bonilla, M Kittaneh, C Kyriakopoulos, RE Ochoa, ... Anticancer research 34 (1), 301-306, 2014 | 25 | 2014 |
| Neoadjuvant nab-paclitaxel and gemcitabine in borderline resectable or locally advanced unresectable pancreatic adenocarcinoma in patients who are ineligible for FOLFIRINOX SL Peterson, M Husnain, T Pollack, A Pimentel, A Loaiza-Bonilla, ... Anticancer research 38 (7), 4035-4039, 2018 | 22 | 2018 |
| Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer. MH O'Hara, TB Karasic, I Vasilevskaya, M Redlinger, A Loaiza-Bonilla, ... Journal of Clinical Oncology 35 (15_suppl), 3545-3545, 2017 | 21 | 2017 |
| A systematic framework to rapidly obtain data on patients with cancer and COVID-19: CCC19 governance, protocol, and quality assurance M Abidi, DM Aboulafia, MK Accordino, JD Acoba, MS Ahluwalia, ... Cancer Cell 38 (6), 761-766, 2020 | 18 | 2020 |
Peter HoseinUniversity of Miami在 med.miami.edu 的电子邮件经过验证
